Syringe-mediated syndemics

AIDS and Behavior

Volumn 15, Issue 7, 2011, Pages 1539-1545

  Bulled, Nicola ^a   Singer, Merrill ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Blood borne pathogens; Disease transmission; HIV AIDS; Syndemics; Syringes

Indexed keywords

ARTICLE; ATTITUDE TO HEALTH; BLOODBORNE BACTERIUM; COMMUNICABLE DISEASE; CROSS INFECTION; DISEASE TRANSMISSION; DRUG ABUSE; HUMAN; SYRINGE;

BLOOD-BORNE PATHOGENS; COMMUNICABLE DISEASES; CROSS INFECTION; DISEASE TRANSMISSION, INFECTIOUS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; NEEDLE SHARING; SYRINGES;

EID: 84855162917     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-009-9631-1     Document Type: Article

References (62)

1. Grund JP, Friedman S, Stern L, et al. Syringe-mediated drug sharing among injecting drug users: Patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med. 1996;4(5):691-703. (Pubitemid 26067875)
2. Hagen H, Des Jarlias D. HIV and HCV infection among injecting drug users. J Mt Sinai Hosp N Y. 2000;67(5&6):423-8.
3. Stimson G, Des Jarlais D, Ball A. Drug injecting and HIV infection: Global dimensions and local responses. New York: Routledge; 1998.
4. Frischer M. Mobility and the Diffusion of Drug Injecting and HIV Infection. In: Stimson G, Des Jarlais D, Ball A, editors. Drug injecting and HIV infection: Global dimensions and local responses. New York: Routledge; 1998. p. 101-14.
5. Reid S. Injection drug use, unsafe medical injections, and HIV in Africa: A systematic review. Harm Reduct J. 2009;6(1):24. Epub ahead of print.
6. Singer M. Something dangerous: Emergent and changing illicit drug use and community health. Prospect Heights, IL: Waveland Press; 2006.
7. Ball A, Rana S, Dehne K. HIV prevention among injecting drug users: Responses in developing and transitional countries. Public Health Rep. 1998;113(Suppl 1):170-81. (Pubitemid 29330158)
8. McCoy C, Rodríguez F. Global overview of injecting drug use and HIV infection. Lancet. 2005;365(9464):1008-9. (Pubitemid 40386768)
9. Stimson G, Adelekan M, Rhodes T. The diffusion of drug injecting in developing countries. Int J Drug Policy. 1996;7:245-55.
10. Bastos F, Barcellos C, Lowndes C, Friedman S. Co-infection with malaria and HIV in injecting drug users in Brazil: A new challenge to public health? Addiction. 1999;94:1165-74. (Pubitemid 29385144)
11. Sharp CP, Lail A, Donfield S, et al. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 Antibodies. J Infect Dis. 2009;200(7):1119-25.
12. Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting Drug uses in Berlin. Int J Epidemiol. 1997;26(6):1359-66. (Pubitemid 28010456)
13. Todd C, Abed A, Strathdee S, et al. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis. 2007;13(9):1327-31. (Pubitemid 47510293)
14. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann Trop Med Parasitol. 2003;97(S1):S29-45. (Pubitemid 37475933)
15. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: Systematic review and meta-analysis. Public Health. 2008;122(10):990-1003.
16. Miller CL, Wood E, Spittal PM, et al. The future face of coinfection: Prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr. 2004;36(2):743-9. (Pubitemid 38685969)
17. Dumchev KV, Soldyshev R, Qian HZ, et al. HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: A cross-sectional survey. Harm Reduct J. 2009;6(1):23. Epub ahead of print.
18. Antonucci G, Vairo F, Iacomi F, et al. Role of hepatitis B virus, hepatitis D virus and other determinants on suppression of hepatitis C viraemia in HIV infected patients with chronic HCV infection: A longitudinal evaluation. Scand J Infect Dis. 2008;40(11-12):928-34.
19. Singer M. Introduction to syndemics: A systems approach to public and community health. San Francisco, CA: Jossey-Bass; 2009.
20. Inciardi J. The war on drugs: Heroin, cocaine, crime, and public policy. Mountain View, California: Mayfield; 1986.
21. Bradley J. Transmission of malaria in drug addicts by intravenous use of narcotics. Am J Trop Med. 1934;14(4):319-24.
22. Derricott J. The history of injecting and needle exchange. 1999. Available at: Http://www.drugtext.org/library/books/needle/hist orym.htm. Accessed 31 Aug 2009.
23. Page JB, Smith P, Kane N. Shooting galleries, their proprietors, and implications for prevention of AIDS. Drugs Soc (New York). 1990;5(1-2):69-85.
24. van Staa AL, Hardon A. Injection practices in the developing world results and recommendations from field studies in Uganda and Indonesia. Amsterdam: Medical Anthropology Unit, University of Amsterdam; 1996.
25. Wyatt H. The popularity of injections in the third world: Origin and consequences for poliomyelitis. Soc Sci Med. 1984;19(9):911-5.
26. Singer M. Pathogen-pathogen interaction: A syndemic model of complex biosocial processes in disease. Virulence 2010; 1(1).
27. Mustanski B, Garofalo R, Herrick A, Donenberg G. Psychosocial health problems increase risk for HIV among urban young men who have sex with men: Preliminary evidence of a syndemic in need of attention. Ann Behav Med. 2007;34(1):37-45. (Pubitemid 47481223)
28. Singer M. Pathogens gone wild?: Medical anthropology and the "swine flu" pandemic. Med Anthropol. 2009;28(3):199-206.
29. Herring DA, Sattenspiel L. Social contexts, syndemics, and infectious disease in northern aboriginal populations. Am J Hum Biol. 2007;19(2):190-202. (Pubitemid 46455664)
30. Singer M, Clair S. Syndemics and public health: Reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17(4):423-41. (Pubitemid 38167896)
31. Fleming A, Ogilvie AC. Syringe needles and mass inoculation technique. Br Med J. 1951;1(4706):543-6.
32. Chaisson R, Bachetti P, Osmond D, Brodie B, Sande M, Moss A. Cocaine use and HIV infection in intravenous drug users in San Francisco. J Am Med Assoc. 1989;261(4):61-5.
33. Thompson SC, Boughton CR, Dore GJ. Bloodborne viruses and their survival in the environment: Is public concern about community needlestick exposures justified? Aust N Z J Public Health. 2003;27(6):602-7. (Pubitemid 38028650)
34. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: A review. Bull World Health Organ. 1999; 77(10):789-800.
35. Singh J, Bhatia R, Gandhi JC, et al. Outbreak of viral hepatitis B in a rural community in India linked to inadequately sterilized needles and syringes. Bull World Health Organ. 1998;76(1):93-8. (Pubitemid 28254983)
36. Frank C et al. The role of antischistosomal mass injection treatment in the spread of hepatitis C virus infection in Egypt. Paper presented at: International conference on emerging infectious diseases, Atlanta, 8-11 March, 1998.
37. World Health Organization. Expanded programme on immunization-changing needles but not the syringe: An unsafe practice. Wkly Epidemiol Rec. 1987;62:345-52.
38. Luby SP, Qamruddin K, Shah AA, et al. The relationship between therapeutic injections and higher prevalence of Hepatitis C in Hafizabad, Pakistan. Epidemiol Infect. 1997;199(3):349-56. (Pubitemid 28025292)
39. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subst Use Misuse. 1998;33(5):1197-212. (Pubitemid 28237013)
40. Chang CJ, Lin CH, Lee CT, Chang SJ, Ko YC, Liu HW. Hepatitis C virus infection among short-term intravenous drug users in southern Taiwan. Eur J Epidemiol. 1999;15(7):597-601.
41. Hersh BS, Popovici F, Jezek Z, et al. Risk factors for HIV infection among abandoned Romanian children. AIDS. 1993;7(12):1617-24. (Pubitemid 24008856)
42. Christensen C. Cluster of HIV-1 infection among children in Indian Hospital in Bombay. Informal report to WHO, September 1998. Copenhagen: Department of Virology, Statens Serum Institute; 1998.
43. Des Jarlais D, Arasteh K, Semaan S, Wood E. HIV among injecting drug users: Current epidemiology, biologic markers, respondent-driven sampling, and supervised-injection facilities. Curr Opin HIV AIDS. 2009;4(4):308-13.
44. Abulrahi HA, Bohlega EA, Fontaine RE, al-Seghaver SM, al-Ruwais AA. Plasmodium falciparum malaria transmitted in hospital through heparin locks. Lancet. 1997;349(9044):23-5. (Pubitemid 27022988)
45. Alavi SM, Alavi L, Jaafari F. Outbreak investigation of needle sharing-induced Malaria, Ahvaz, Iran. Int J Infect Dis. 2009; [Epub ahead of print].
46. Cruz I, Morales MA, Noguer I, Rodriguez A, Alvar J. Leishmania in discarded syringes from intravenous drug users. Lancet. 2002;9312:1124-5. (Pubitemid 34270740)
47. Lawn SD. AIDS in Africa: The impact of coinfections on the pathogenesis of HIV-1 infection. J Infect. 2004;48:1-12. (Pubitemid 38072197)
48. World Health Organization, Health Evidence Network. HIV/ HCV Coinfection. Updated 05 August 2009. Available at: Http://www.euro.who.int/HEN/Syntheses/ hepatitisC/20050411-7. Accessed 5 Sep 2009.
49. van Geertruyden J, D'Alessandro U. Malaria and HIV: A silent alliance. Trends Parasitol. 2007;23:465-7. (Pubitemid 47465095)
50. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: A cohort study. Lancet. 2000;356:1051-6.
51. Moriuchi M, Moriuchi H, Mon HM, Kanbara H. Dichotomous effects of Plasmodium falciparum antigens on expression of human immunodeficiency virus (HIV) coreceptors and on infectability of CD4 cells by HIV. J Infect Dis. 2002;186(8):1194-7. (Pubitemid 35177128)
52. den Boer M, Alvar J, Davidson R, Ritmeijer K, Balasegaram M. Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs. 2009;14(3):395-410.
53. Oliver M, Bararo R, Medrano F, Moreno J. The pathogenesis of leishmania/HIV co-infection: Cellular and immunological mechanisms. Parasitology. 2003;97(Suppl 1):79-98.
54. Zhao C, Thibault S, Messier N, Ouellette M, Papadopoulou B, Tremblay MJ. In primary human monocyte-derived macrophages exposed to human immunodeficiency virus type 1, does the increased intracellular growth of Leishmaniainfantum rely on its enhanced uptake? J Gen Virol. 2006;87:1295-302.
55. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: The influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis. 2008;46:1702-9. (Pubitemid 351706767)
56. Trudel N, Garg R, Messier N, Sundar S, Ouellette M, Tremblay MJ. Intracellular survival of leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis. 2008;198:1292-9.
57. Mathur P, Samantaray JC, Vajpayee M, Samanta P. Visceral leishmaniasis/human immunodeficiency virus co-infection in India: The focus of two epidemics. J Med Microbiol. 2006;55: 919-22. (Pubitemid 43974699)
58. Burnet M, White D. Natural history of infectious disease. Cambridge: Cambridge University Press; 1972.
59. Global Infectious Diseases and Epidemiology Online Network (GIDEON). Emergence of infectious diseases in the 21st Century. 2008. Available at: Http://www.gideononline.com/blog/2008/03/ 05/emergence-of-infectious-diseases- in-the-21st-century/. Accessed 5 Sep 2009.
60. Woolhouse ME, Gowtage-Sequeria S. Host range and emerging and reemerging pathogens. Emerg Infect Dis. 2005;11(12):1843-7.
61. Singer M. Drugging the poor: Legal and illegal drug industries and the structuring of social inequality. Prospect Heights, IL: Waveland Press; 2008.
62. McKnight C, Des Jarlais D, Perlis T, et al. Syringe exchange programs-United States, 2005. MMWR Morb Mortal Wkly Rep. 2007;56(44):1164-7.